Fredun Pharmaceuticals Limited
Current Price
₹2,424.65
As of 20 May 2026
Market Cap
₹1.27K Cr
As of 20 May 2026
Generic Pharma Pivoting to Longevity Science (Pet Care + NAD+ Wellness + Hormone Therapeutics)
Report updated: 2026-05-16
Fredun Pharmaceuticals Limited
36-year-old generic pharma pivoting to longevity science — Medhora-family company branching out into pet care (Freossi, Wagr), nutraceuticals, hormone therapeutics and NAD+ cellular wellness (DAULCEL). Management guides to Rs.800 Cr revenue and Rs.90 Cr PAT by FY28-FY29 with >=51% from new-age businesses by FY32.
Rs.2,359
Share price (16 May 2026)
Rs.330 Cr
Market cap (Micro Cap)
Rs.426 Cr
9M FY26 revenue
Mgmt guides FY26 full year Rs.550-580 Cr
Rs.27 Cr
9M FY26 PAT
FY25 PAT Rs.20.8 Cr; H1 FY26 op cash flow turned positive
16%
Q3 FY26 EBITDA margin
+384 bps YoY, 4-year high
Rs.80-85 Cr
Receivables (Sep 2025)
Down from Rs.177 Cr Mar-25 after Rs.380 Cr collection
Stock Funda Summary
- 36-year-old niche pharma (BSE 539730 / NSE FREDUN) actively diversifying into wellness, pet care, hormone therapeutics, and NAD+ longevity (DAULCÉL).
- H1 FY26 op cash flows turned positive (vs FY25 CFO -Rs.31 Cr)
- Q3 FY26 OPM 16% (+384 bps YoY, 4-yr high)
- Q4 result due 25 May 2026 with final dividend + bonus shares on agenda.
- Mgmt guides FY28 ~Rs.800 Cr revenue + Rs.90 Cr PAT (vs FY26 ~Rs.426 Cr 9M)
- FY27 segment exits Gx Rs.60 Cr / Pet Care Rs.42 Cr / Nutra Rs.26 Cr.
- Five watch items tracked: cash flow normalisation, Palghar 40k sq ft capex (Oct 2026), margin sustainability via mix shift, debtor days normalisation, SEBI clearance.
- Promoter 36% concentrated in Medhora family.
- Live event timeline tracks every BSE filing, concall, and launch.